MARKET

MYO

MYO

Myomo
AMEX

Real-time Quotes | Nasdaq Last Sale

2.140
+0.100
+4.90%
Closed 16:00 05/26 EDT
OPEN
2.160
PREV CLOSE
2.040
HIGH
2.200
LOW
2.080
VOLUME
11.47K
TURNOVER
20.09K
52 WEEK HIGH
14.35
52 WEEK LOW
1.970
MARKET CAP
14.73M
P/E (TTM)
-1.2321
1D
5D
1M
3M
1Y
5Y
11 Best Robotics Stocks Under $10
In this article, we discuss the 11 best robotics stocks under $10. If you want to skip our detailed analysis of the robotics industry, go directly to 5 Best Robotics Stocks Under $10. Many key industries around the globe are increasingly adopting the use o...
Insider Monkey · 1d ago
Stocks That Hit 52-Week Lows On Monday
  On Monday, 149 companies reached new 52-week lows.
Benzinga · 3d ago
Recap: Myomo Q1 Earnings
Myomo (AMEX:MYO) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Myomo beat estimated earnings by 22.64%, reporting an EPS of $-0.41 versus an estimate of $-0.53.
Benzinga · 05/11 22:33
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 24.07% and 35.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 22:05
Myomo Says $1.7M Of License Revenue Is Expected To Be Recorded In Q2, Assuming Receipt Of Final Payment Of License Fee From China JV
“As the growing pipeline of MyoPro candidates converts into orders, we continue to expect year-over-year product revenue growth in 2022. Assuming receipt of the final payment of the license fee from our joint
Benzinga · 05/11 20:33
Myomo Q1 EPS $(0.41) Beats $(0.53) Estimate, Sales $3.90M Beat $2.85M Estimate
Myomo (AMEX:MYO) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.53) by 22.64 percent. This is a 28.07 percent increase over losses of $(0.57) per share from the same
Benzinga · 05/11 20:32
Myomo GAAP EPS of -$0.41 beats by $0.12, revenue of $3.87M beats by $1.01M
Myomo press release (NYSE:MYO): Q1 GAAP EPS of -$0.41 beats by $0.12. Revenue of $3.87M (+65.4% Y/Y) beats by $1.01M.
Seekingalpha · 05/11 20:14
-- Earnings Flash (MYO) MYOMO Reports Q1 Revenue $3.9M, vs. Street Est of $2.86M
MT Newswires · 05/11 16:27
More
No Data
Learn about the latest financial forecast of MYO. Analyze the recent business situations of Myomo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MYO stock price target is 14.38 with a high estimate of 23.00 and a low estimate of 7.50.
High23.00
Average14.38
Low7.50
Current 2.140
EPS
Actual
Estimate
-0.48-0.36-0.24-0.12
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 16
Institutional Holdings: 1.72M
% Owned: 25.06%
Shares Outstanding: 6.88M
TypeInstitutionsShares
Increased
5
181.43K
New
2
182.53K
Decreased
3
53.28K
Sold Out
7
253.27K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.46%
Healthcare Equipment & Supplies
+0.52%
Key Executives
Chairman/President/Chief Executive Officer/Director
Paul Gudonis
Chief Financial Officer
David Henry
Chief Marketing Officer
Clifford Conneighton
Other
Harry Kovelman
Other
Micah Mitchell
Lead Director/Independent Director
Thomas Kirk
Independent Director
Thomas Crowley
Independent Director
Amy Knapp
No Data
No Data
About MYO
Myomo, Inc. is a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The Company develops and markets the MyoPro product line. Its MyoPro is a myoelectric-controlled upper limb brace (orthosis), which is a rigid brace used for the purpose of supporting a patient's weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs) in the home and community. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. It primarily provides devices directly to patients and bill their insurance companies. It also sells its products through various other sales channels, including orthotic and prosthetic (O&P) providers, the Veterans Administration (VA) and to its distributors in certain accounts and geographic markets.

Webull offers kinds of Myomo Inc stock information, including AMEX:MYO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYO stock methods without spending real money on the virtual paper trading platform.